Quick Answer
Telomir Pharmaceuticals, Inc. reported Net Income of -$10.41 million for fiscal year 2025.
Telomir Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$10.41M | +37.0% |
| 2024 | -$16.53M | -26.5% |
| 2023 | -$13.07M | -1430.4% |
| 2022 | -$854.1K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.10M | +81.6% | +78.3% |
| June 30, 2025 | -$5.07M | -265.0% | -132.6% |
| March 31, 2025 | -$2.18M | +65.1% | +63.6% |
| September 30, 2024 | -$5.99M | -250.1% | -331.3% |
| June 30, 2024 | -$1.39M | +10.4% | +77.8% |
| March 31, 2024 | -$6.25M | -1195.1% | +32.9% |
| December 31, 2023 | -$9.33M | — | -445.0% |
| September 30, 2023 | -$1.71M | — | -10.4% |
- Telomir Pharmaceuticals, Inc. showed an increase of +37.0% in Net Income compared to the prior fiscal year.
- Over the 2022–2025 period, Telomir Pharmaceuticals, Inc.’s net income has declined by 1119.1% (from -$854.1 thousand to -$10.41 million).
- The most recent figure is from Telomir Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: